ReviewPharmaceutics2026
Photo- and Immunotherapy Interface: Can Dendritic Cell Vaccines Overcome the Limitations of PDT?
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Photodynamic therapy (PDT) occupies an important place in the arsenal of cancer treatment modalities; however, its efficacy is primarily limited by the local nature of its effects and by tumor cell resistance. The aim of this review is to analyze the fundamental principles and biological consequences of PDT, to summarize current data on the molecular and cellular mechanisms determining its efficacy, and to consider strategies for overcoming its limitations. Particular attention is paid to the mechanisms underlying resistance development and to the role of switching from non-immunogenic to immunogenic cell death in shaping the antitumor response. The potential integration of PDT with dendritic cell vaccination is considered a promising strategy for overcoming these limitations. The potential of vaccine-based approaches to activate specific antitumor immunity in aggressive cancers is highlighted, with emphasis on the advantages of dendritic cell vaccines in addressing the limitations of conventional PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.